Skip to content
The Galveston

Novo CEO says obesity market won't be winner-take-all battle with Lilly

By Michael Erman NEW YORK, Aug 13 (Reuters) - Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like

Sources and story details